drugs (ATDs) such as methimazole and propylthiouracil (PTU) were still used as the preferred treatment for GD in China and other countries in Asia. The main concern among general practitioners is iodine-131 induced hypothyroidism, because many rural patients do not comply with lifelong regular levothyroxine (L-T4) replacement (2) . Nevertheless, changing economic factors and high relapse rates observed after discontinuation of ATD treatment, the use of iodine-131 has dramatically increased.
Although iodine-131 therapy is generally well tolerated, potential side effects may occur, such as radiation-induced thyroiditis, sialadenitis, bone marrow depression, pulmonary fibrosis, and rarely induction of a second primary malignancy (6) (7) (8) . Besides, transient or chronic hypospermia can be detected (9, 10) , as well as possible early onset of menopause (11) and menstrual cycle abnormalities (12) . The mentioned severe side effects were all observed in those who receive high dose iodine-131 treatment in thyroid cancer instead of the lower doses used in the treatment of GD. Considering the much lower dose of iondine-131 administrated in GD than in cancer, we investigated whether iodine-131 treatment in GD would increase pregnancy loss and alter fetal development. Here, we aimed to investigate the pregnancy outcomes of childbearing-age women with GD who inadvertently received iodine-131 treatment in our hospitals.
Materials and Methods

Patients
From May 2005 to December 2015, 2,276 childbearingage (from 20 to 40 years old ) women with GD received iodine-131 treatment in Ruijin Hospital and Ruijin Hospital North (Shanghai Jiaotong University, School of Medicine, Shanghai, China) and were retrospectively enrolled. We excluded patients who delivered before iodine-131 treatment, and were unwilling to participate or failed to appear for follow-up for this study. Eventually, we enrolled 69 pregnant women and 1346 women who were not pregnant during the whole treatment and follow-up period.
Hyperthyroidism Treatment
The diagnoses of hyperthyroidism were based on serum free triiodothyronine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone (TSH) levels, 24 hours thyroid radioactive iodine uptake (RAIU). Thyroid weight was based on color Doppler ultrasonography inspection and palpation. Accordingly, nuclear medicine physicians calculated and checked the required activity of iodine-131 (Shanghai Anshengkexing Pharmaceutical Co. Ltd., Shanghai, China) for individual patients. When necessary, repeated treatments were performed as needed in other studies (13) . Before iodine-131 treatment, women of childbearing age underwent routine detection of serum β-HCG, which was an endocrine indicator of pregnancy. If the pregnant woman was found to have severe hyperthyroidism, she was advised to interrupt the pregnancy and receive treatment two months later. If the woman became pregnant within 6 months after iodine-131 treatment, and her hyperthyroid symptoms persisted unabated, the patient was recommended for therapeutic abortion in accord with the maternal condition and fetal development status.
Patients were informed of radiation safety guidelines before iodine-131 treatment, and they all agreed and signed informed consents.
Follow-up
The follow-up was divided into two parts. One was regular follow-up after iodine-131 treatment for all women enrolled in our study, the other was specific for pregnancy and birth follow-up after iodine-131 for 69 pregnant women. Regular follow-up observation after iodine-131 treatment was conducted at 1 month, 3 months, 6 months and 1 year after iodine-131 treatment. Measurements of serum FT3, FT4 and TSH levels of the treated patients were performed to indicate thyroid functional restoration and measurement of the volume of thyroid was conducted at the same time. During the follow-up, if women had significantly increased FT3 or FT4, and goiter (over I degree goiter) after treatment, they had another iodine-131 treatment (3~6 months after previous treatment) as an outpatient. If women had slightly increased FT3, FT4 or TSH without goiter, they received moderate anti-thyroid drugs (ATDs) or levothyroxine (L-T4), or continued observation as an ordinary outpatient. As for 69 pregnant women, they first had serum β-Human chorionic gonadotropin (hCG) and mode-B ultrasonography for baby at 4 to 8 gestational weeks to confirm pregnancy. The thyroid functions of pregnant women were monitored every 4 weeks. The thyroid function was measured at 6 months postpartum, and the height, weight and intelligence development of babies were also monitored at the same time.
Pregnancy management
Management of thyroid function during pregnancy: i) According to the follow-up measurements of thyroid function and related hormones at 1 months, 3 months, 6 months and 1 year after iodine-131 treatment, the treated patients were classified in three thyroid function states: euthyroid, subclinical hyperthyroid and subclinical hypothyroid; ii) The treated women patients were administered adjustable doses of L-T4 as needed, depending on the serum TSH level; iii) The treated L (reference value range: 0.35-4.94 mU/L). Before treatment, each individual's 24 hour thyroid RAIU was more than 50%. Accordingly, the nuclear medicine physicians calculated and checked the required activity of iodine-131 for individuals, and considered much concern about hypothyroidism after treatment. The administered patient-specific doses were conservatively among low and medium dosage, most ranged from 111 to 333 MBq (average 222 MBq).
Analysis of the 69 pregnant women
The nuclear medicine physicians calculated and checked the required activity of iodine-131 for individuals, 254.9 ± 99.9 MBq (range from 92.5-740 MBq) of iodine-131 (Table 1, Figure 1A ). Before pregnancy, 55 patients received one single dosage, 11 patients received two treatments, 1 patient was treated three times (No.67) and the other 2 had four treatments (No. 68 and No. 69). The interval between first and second iodine-131 treatment was 7 ± 6 months, interval between second and third iodine-131 treatment was 6 ± 2 months, and interval between second and third iodine-131treatment was 6 ± 1 months ( Figure 1B ).
On the other hand, the interval between pregnancy and iodine-131 treatment was 22 ± 16 months (range from 4-76 months) in all 69 participants. Because an increased risk of miscarriage, fetal or neonatal death is correlated with higher maternal TSH levels in pregnancy (14) , the mothers' serum TSH levels should be manipulated to lower levels before they become pregnant. After iodine-131 treatment, 50 women patients were subclinically hypothyroid, and they needed L-T4 to control TSH and circulating thyroid hormones to maintain normal thyroid function. The administration doses were 55 ± 25 μg/d. Pregnant women were administered adjusted doses of L-T4 depending on TSH levels measured every 4 weeks to control TSH levels below 2.5 mU/L. The administered doses during pregnancy were changed from 12.5-25μg/d. 7 patients were subclinically hyperthyroid after iodine-131 treatment, and their administered PTU doses were 25 ± 12.5 mg/d. While the other 12 euthyroid patients had normal thyroid function test results.
A retrospective analysis showed that the morbidity of birth disorders in the region was 1.06% in the recent year and congenital heart disease, multi finger (toe), hypospadias, cleft lip, and palate and deformity of external ear were the 5 top birth defects. Compared to infants born with no birth defects, male, low birth weight, twins and multiple births were statistically higher in infants (15) . Complication of labor and pregnancy, pregnant infection, fetal growth restriction (FGR), birth disorders can be the first five reasons related to stillbirth (16) . In the 8th and 16th gestational weeks, the 69 pregnant women received mode-B ultrasonography studies to detect their fetal women were recommended to avoid pregnancy until more than 6 months after iodine-131 treatment. L-T4 for hypothyroid patients was administered and PTU was prescribed for hyperthyroid patients to control the serum TSH level below 2.5 mU/L. The objective serum TSH level in pregnancy ranges from 0.1 to 2.5 mU/L in early stage, from 0.2 to 3.0 mU/L in middle stage and from 0.3 to 3.0 mU/L in late stage.
Those pregnant women enrolled in our study underwent antenatal care regularly in order to monitor the normal growth and development status of the fetuses, and healthy condition of mothers, mainly including fetal malformation screening, periodic mode-B ultrasonography, and amniotic cell karyotype analysis would be done if it was necessary to further confirm numerical and structural fetal chromosomal aberrations.
Statistical analysis
Statistical analysis was carried out using software package SPSS17.0, and statistically significant differences were assessed by one-way ANOVA followed by Tukey's test. A p value of less than 0.05 was considered to be statistically significant. All descriptive data was reported as median ± standard deviation (x̅ ̅ ± s).
Results
Among 2,276 childbearing-age women with GD who received iodine-131 treatment during May 2005 to December 2015, 769 women delivered before iodine-131 treatment, 92 women were unwilling to participate or failed to appear for follow-up for this study for individual reasons except for healthy problems. The reasons we failed to follow-up were mainly that patients came from all around China often went back to their hometown after treatment, and thus it was hard to follow when they changed their contact information. It was also hard to look for their information in researching birth registries in the region because it didn't cover all distant places around China. Those women were excluded from our study. Finally, 1,346 women did not become pregnant after therapy and 69 successfully pregnant women were enrolled for further analysis. They were all hyperthyroid before pregnancy, and received iodine-131 treatment in our hospital. Some patients received treatment several times, and the earliest treatment started from May 3nd, 2005. The circulating thyroid hormone hormones levels were measured by chemiluminescent immunoassay, and the results showed the FT3 levels of these patients before treatment were all above 5.7 pmol/L (reference value range: 2.63-5.70 pmol/L), FT4 levels were all above 19 pmol/L (reference value range: 9.01-19.04 pmol/L), and TSH levels were less than 0.3 mU/ Thyroid function management development stage. The inspections showed normal growth and development status of the fetuses. The predictive analysis of prenatal screening in the 16th gestational week indicated the mothers were at low risk for fetuses with Down's syndrome. Two of these mothers received amniotic cell karyotype analysis in the 20th gestational week to diagnose whether their fetus' chromosomes were indicative of a malformation abnormality, and the results showed no structural change in these cases. Fetal quickening, heart monitoring and mode-B ultrasonography inspections were performed once every 4 weeks after the 24th gestational week to monitor the fetuses developmental status, and to assess whether the fetuses were all in normal condition. One treated patient became pregnant 4th months after iodine-131 treatment (No.67), and mode-B ultrasonography inspection showed the mother conceived dizygotic twins. All inspection parameters of both twins remained normal during pregnancy. The treating physicians discussed in detail and deliberatively reached an agreement to continue the pregnancy with approval of the patient's family. Among these 69 pregnant patients with successful childbirth, 63 mothers had singleton pregnancies, and 3 had dizygotic twin pregnancies (No. 37, 43 and 67), and among 2 two singleton pregnancies, one successively (No. 66) gave birth to two baby boys, while the other (No. 58) had a baby girl and a baby boy, and 1 had monozygotic twins (No. 36) with two identical baby boys.
The sex ratio of 75 newborn infants was 41 boys vs. 34 girls (Figure 2) . In all 75 babies, 65 babies were fullterm birth while only 9 were premature (4 ± 1 weeks early). Their birth weight was 3.2 ± 0.5 kg; 6 newbirth babies (No. 27, 42, 43, 49, 69) were considered to be low birth weight infants (< 2.5 kg) while the other 5 babies' (No. 8, 17, 25, 39, 52) were high birth weight (> 4 kg) (Figure 3) .
Of 75 newborn infants, screening for evidence of neonatal diseases, done by analysis of blood samples collected from their heels, showed normal blood physiological and biochemical indices and TSH levels (0-10 mU/L) in the normal range. To date, the infants of iodine-131-treated mothers show the same developmental progression as do the children of untreated euthyroid mothers with respect to when they sit, crawl, stand, walk, run and talk. The oldest child is now 7.4 years old, and this child's thyroid function, developmental status and intelligence does not show any difference compared to children of the same age. One premature infant of low birth-weight is now 4.7 years old, and his weight at 2 years' old is lighter than children of the same age, but thyroid function and intelligence is the same as his peers.
Analysis of the 1346 women who were not pregnant
The times of iodine-131 treatment in 1346 women who were not pregnant range from 1 to 5. These 1346 women that were hyperthyroid were administrated iodine-131 at different times, the administered amount was 237. Figure 4A ). Among 1346 pregnant women, 289 women who had a second administration, the interval time between first and second time was 6.5 ± 3.9 months, 44 women who had a third administration, the interval time between second and third time was 7.1 ± 4.6 months, 7 women who had a forth administration, the interval time between third and fourth time was 8.3 ± 4.6 months, 2 women who had a fifth administration, the interval time between fourth and fifth time was 5.0 ± 0 ( Figure 4B ). After iodine-131 treatment, 70% of women turned to subclinical hypothyroid and administered LT-4 (dose ranges from 50 to 100 mg), 20% of women turned to subclinical hyperthyroid and administered PTU (dose ranges from 12.5 to 50 mg). While the other 10% of euthyroid patients had normal thyroid function test results. All patients had no other special side reactions reported so far. Until December, 12 th , 2015, 5 were found pregnant among the 1346 patients (gestational weeks ranged from 6 to 9 months). 3 of them were subclinically hypothyroid and administered LT-4, 1 of them turned to subclinical hyperthyroid and administered PTU and of them 1 had normal thyroid function test results. We had further follow-up and observed 2 of them had full-term delivery, however one of newborn babies died after birth because of congenital heart disease and the other died 3 days after birth because of cerebral hemorrhage. These two babies did not undergo an autopsy. Two patients were found pregnant among the 1346 patients who took the iodine-131 treatment, thus they chose to take PTU to control the hyperthyroidism and put off the iodine-131 treatment until after delivery ( women had a second administration, the interval time between first and second time was 6.5 ± 3.9 months, 44 women had a third administration, the interval time between second and third time was 7.1 ± 4.6 months, 7 women had a forth administration, the interval time between third and fourth time was 8.3 ± 4.6 months, 2 women had a fifth administration, the interval time between fourth and fifth time was 5.0 ± 0 months. 
Discussion
Although iodine-131 treatment of hyperthyroidism has been used in clinical practice for over half a century, data about possible damage to the female gonads after administration for therapeutic purposes are still inconclusive. There are only a few literature reports dealing with this issue and the majority of them deal with high dose treatment for thyroid cancer (17) . For women patients, the effects of iodine-131 therapy on gonadal function are a critical consideration because many are of childbearing-age and wish to have healthy children. Female gonads may be affected during iodine-131 therapy from circulating radioiodine in the blood, as well as radiation from the bladder and bowel sequestration during and for a few days post therapy. Therefore, patients are instructed to drink large amounts of fluids and use laxatives if constipated in order to avoid unnecessary radiation to the ovaries (18) .
According to the guidelines established by the Society of Nuclear Medicine and Molecular Imaging, female patients who have the potential to be pregnant must always be tested for pregnancy using a urine or serum β-HCG test before iodine-131 treatment (19) . Iodine-131 therapy is absolutely contraindicated in pregnant women and one attempts to avoid inadvertent exposure and this continues to be recommended in the literature. However, Hyer S, et al. (20) demonstrated that exposure to iodine-131 at this very early stage of pregnancy (pre implantation) is unlikely to result in malformations or thyroid dysfunction in surviving embryos; only exposure during thyroidogenesis (from 10 weeks gestation) and organogenesis (from 2 weeks gestation) may result in fetal thyroid ablation, birth defects and in later life, growth retardation and reduction in IQ. Generally speaking, women are advised to delay pregnancy at least 6 months after iodine-131 treatment in China, at which time there should be no risk of them suffering from miscarries or other dangers (21) .
Another concern regarding iodine-131 treatment for childbearing-age women in China is the possible result of hypothyroidism. Nevertheless, many experts in western countries consider hypothyroidism after a single dose of iodine-131 a desired outcome of therapy because it avoids frequent office visits and laboratory testing to detect the late onset of hypothyroidism and thereby decreasing the risk of untreated, persistent, or recurrent hyperthyroidism (19) . Once identified, use of replacement L-T4 can adjust the patients' thyroid function to the normal range diminishing possible concern regarding hypothyroid induction.
Previous studies in female patients have shown no significant effects of iodine-131 in treating thyroid cancers on fertility rate, birth weight, or congenital anomalies in offspring (22) (23) (24) (25) (26) (27) (28) (29) . In our study, we have the same experience in treating patients for GD. Among these 26 women patients we observed only successful pregnancy and childbirth, and no birth defects or other malformations were detected.
Of course, the present study has several limitations. The first is the retrospective nature of the study. Another limitation is the relatively small number of patients, which can lead to selection bias. Considering the nonzero frequency of mild and moderate birth disorders in untreated pregnancies, the same fraction would also be expected in the treated group. We haven't seen it yet, mainly due to the relatively small number of patients we have had so far. Our study is still in progress at present, and more patients and cases will be included in the next stage of our study. We will also concentrate on expanding the sample size, and strengthen the followup of treated patients by cooperation of obstetrics with endocrinology. Thus we may be able to get more powerful analysis on birth disorders, still births, normal live births and so on. We expect we can get a more authoritative data statistics in the next few years. For these reasons, we suggest further clinical trials should be undertaken, especially a prospective and multicenter study.
In conclusion, no significant harm to fetuses has been observed on child-bearing age women with GD who received iodine-131 treatment before pregnancy. No significant risk of abnormal fetal development has been observed on pregnant women with GD after a 6-month period of iodine-131 treatment. In order to more firmly establish these conclusions, it will be necessary to study larger numbers of subjects in a prospective multicenter study.
